Project Grant R01AG103531
- The National Institute on Aging awarded New York University $708,137 on February 1, 2026, under the Aging Research program (CFDA 93.866) to develop and validate technologies for probing the biophysical properties of aging cells. The funded work centers on developing genetically encoded multimeric particles (GEMs) as high-throughput microrheology probes to measure the physical properties of cell interiors—particularly within organelles including the nucleus, cytoplasm, endoplasmic reticulum,...
- The National Institute on Aging awarded New York University $466,125 under the Aging Research program (CFDA 93.866) on January 15, 2026, to develop innovative magnetic resonance imaging analysis tools for identifying microstructural biomarkers of skeletal muscle health across the lifespan. The project, titled "(Micro)structural Biomarkers of Skeletal Muscle Health Across the Lifespan," addresses sarcopenia—a leading cause of disability and mortality in aging populations—by creating...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded $533,500 to the Buck Institute for Research on Aging on July 15, 2026, under the Aging Research program (CFDA 93.866). The award funds examination of the role of autonomic innervation in muscle stem cell aging. The research investigates the functional link between autonomic nervous system neurons and muscle stem cells using Drosophila melanogaster as a model organism. The project will refine...
- The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $690,898 on September 15, 2026, under the Aging Research program (CFDA 93.866) to conduct functional genetic analyses of healthspan in humans. The recipient will identify shared genetic architecture underlying age-related diseases and aging-related traits, experimentally validate the regulatory roles of healthspan-associated non-coding variants and their target genes, and elucidate molecular...
- The National Institute on Aging awarded Albany Medical College $246,000 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate inter-organelle dynamics during aging in eukaryotic cells. The work will characterize spatial contexts of inter-organelle communication using C. elegans as a model system to identify organellar signatures that develop during aging and proteostasis decline, establishing a platform to understand how aging impacts organelle interactions and...
- The National Institute on Aging awarded the University of Pennsylvania $2,809,832 on February 1, 2026, under the Aging Research program (CFDA 93.866) to investigate epigenetic mechanisms driving cellular aging and age-associated disease. The award funds four integrated research projects examining chromatin homeostasis ("chromostasis") and senescence-associated secretory phenotype (SASP) in aging tissues. The research hypothesizes that age-related epigenetic changes result from...
- The National Institute on Aging, a component of the Department of Health and Human Services National Institutes of Health, awarded $198,728 to The Rockefeller University on February 21, 2026, under the Aging Research program (CFDA 93.866) to identify cell type-specific RNA expression and regulatory changes in entorhinal cortex clinical samples of Alzheimer's disease. The funded work develops and applies a novel methodology called CLIP-FANS (crosslinking immunoprecipitation-fluorescence activated...
- The National Institute on Aging awarded The Scripps Research Institute $645,242 on July 1, 2026, under the Aging Research program (CFDA 93.866) to conduct research on chemical modulation of proteostasis to promote longevity and healthy aging. The award funds development of chemical and computational tools to selectively attenuate polysome-mediated translation in vivo, quantify protein conformational changes across the neuronal proteome with age, and assess healthy aging and behavior in...
- The National Institute on Aging awarded the University of Rochester $227,250 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate macrophage spatial heterogeneity in regulating hematopoietic aging and inflammation-related stem cell dysfunction. The research examines how resident macrophages in different bone marrow microenvironments regulate hematopoietic stem cell (HSC) division symmetry and fitness during aging. Using intravital microscopy and HSC reporter...
- The National Institute on Aging awarded Weill Medical College of Cornell University $218,728 on March 3, 2026, under the Aging Research program (CFDA 93.866) to investigate vulnerable cell populations in aging-induced circadian clock remodeling and disruption. The recipient will conduct high-throughput single-nucleus RNA sequencing of flash-frozen tissues from young and aged mice sampled every four hours over two days in constant darkness. In the first aim, the investigator will profile seven...
The National Institute on Aging awarded New York University $705,405 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate how changes in nuclear physical properties during cellular senescence drive transcriptional and splicing dysregulation characteristic of aging. The funded research measures nuclear biophysical properties across multiple length scales using a toolkit including genetically encoded multimeric nanoparticles (nucGEMS, 40–50 nanometers), newly developed larger GEMs (140 nanometers), synthetic protein crystals (200–500 nanometers), and syndrop condensates (50 nanometers–3 micrometers). Researchers will perform microrheology to quantify nuclear fluidity, viscosity, and dynamics in young versus aged cells across multiple senescence models. The project also investigates mechanisms driving these biophysical changes. Prior work using the GEMs platform discovered that nuclear fluidity increases dramatically during both CDK4/6 inhibition and replicative senescence, contrary to expectations of chromatin rigidification. Inhibiting H3K27 trimethylation suppressed these physical changes and increased replicative lifespan after CDK4/6 inhibitor treatment, suggesting potential therapeutic targeting of age-related nuclear changes. Performance of work occurs in New York, New York, with a period of performance from September 1, 2026, through May 31, 2031. This is a Project Grant award.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $705.4k | 8/31/26 |